Rho GTPase activating protein 40Genealiases: C20orf95 · dJ1100H13.4
Q-omics provides the consensus-scored ARHGAP40 profile across patient tissues and cancer cell-line models. ARHGAP40 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGAP40 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ARHGAP40 RNA expression shows 11,575 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where ARHGAP40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP40 survival associations across molecular data types. ARHGAP40 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP40 RNA expression–survival associations across cancer types. High ARHGAP40 expression shows unfavorable associations in KIRC, LIHC, LGG, UCEC, LUSC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGAP40 RNA expression.
This table summarizes ARHGAP40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ARHGAP40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP40 shows lower tumor expression in HNSC, KIRC, KICH and BRCA and higher tumor expression in LUAD and COAD. The HNSC box plot shows higher ARHGAP40 RNA expression in normal versus tumor tissue (log2 FC = −1.841, t-test p < 0.001).
This table shows molecular features associated with ARHGAP40 in patient tissues and cancer cell lines. In patient samples, ARHGAP40 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP40 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
